Tag Archives: Systemic

Systemic Sclerosis-Associated PAH Genomic Signature Differs From ILD

January 09, 2019 Share this content: When patients with interstitial lung disease were included, 4 genes (S100P, CD8B1, CCL2, and TIMP1), along with male sex, were predictive of pulmonary arterial hypertension. Patients with systemic sclerosis (SSc)-associated pulmonary arterial hypertension (PAH) and patients with SSc-associated interstitial lung disease (ILD) exhibit similar but distinct gene expression profiles,… Read More »

FDA Approves Adcetris (brentuximab vedotin) in Combination with Chemotherapy for Adults with Previously Untreated Systemic Anaplastic Large Cell Lymphoma or Other CD30-Expressing Peripheral T-Cell Lymphomas

Print this page BOTHELL, Wash.–(BUSINESS WIRE)–Nov. 16, 2018– Seattle Genetics, Inc. (Nasdaq:SGEN) today announced a new approval for Adcetris (brentuximab vedotin) in combination with CHP chemotherapy (cyclophosphamide, doxorubicin, prednisone) from the U.S. Food and Drug Administration (FDA) for adults with previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL),… Read More »